Auxilium Pharmaceuticals — Investor Presentation (January 2009)
45 slides from Auxilium Pharmaceuticals's investor presentation, Jan 12, 2009

Slide 1: January 2009
January 2009 Exhibit 99.1 (NASDAQ: AUXL)

Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,

Slide 3: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories

Slide 4: Anticipated XIAFLEX Events 2009-2010
• File BLA for Dupuytren's Contracture (early 2009) • Decision from FDA on priority review (60 days post-BLA filing) • Dupuytren's Contracture safety data available (post-BLA filing) • Complete enrollment in Peyronie’s Phase IIb (1Q09) • Top-line results of Peyronie's Phase IIb Study (4Q09) • FDA Ap

Slide 5: Pipeline Continues to Advance
Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy

Slide 6: Strong Strategic Partner for XIAFLEX in EU Validates Market Potential
Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Increasing tiered royalties based on sales of XIAFLEX in Pfizer’s terri

Slide 7: XIAFLEX Driver of Long-Term Growth
XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA

Slide 8: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights gener

Slide 9: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be rese

Slide 10: Current Treatment Options Require Invasive Surgery or Are Unapproved
Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation

Slide 11: XIAFLEX Offers an Improved Mechanism of Action
XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow clea

Slide 12: Thoroughly Researched Dupuytren's Clinical Program for XIAFLEX
Thoroughly Researched Dupuytren’s Clinical Program for XIAFLEX Study Name Country Design Treated Patients (N) DUPY-202 U.S. DB 73 DUPY-303 U.S. DB 35 DUPY-851/852 U.S. DB 5 DUPY-853 U.S. DB 17 U.S. OL CORD II AUS DB & OL 63 JOINT I U.S. OL 195 JOINT II AUS/ EU OL 379 Pharmacokinetics U.S. 16 1082 CO

Slide 13: CORD I - Largest Double-blind, Placebo-controlled Trial
CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture • Primary endpoint is reduction in contracture to within – o of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Secon

Slide 14: il & é 49.1% 45.7% 50.2% quauranosduyy yar (%) 1U8d18q 847% quauranoiduyy yA (%)
il & é 49.1% 45.7% 50.2% quauranosduyy yar (%) 1U8d18q 847% quauranoiduyy yA (%) Wed. 64% (3) ssazang ya juaaieg

Slide 15: XIAFLEX Phase III AE and SAE Rates
XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Complex Regional Pain Syndrome 1 0.04% Total 7 0.

Slide 16: XIAFLEX Offers a Non-Invasive Treatment for Dupuytren's Contracture
XIAFLEX Offers a Non-Invasive Treatment for Dupuytren’s Contracture

Slide 17: Dupuytren's Key Clinical Takeaways
Dupuytren’s Key Clinical Takeaways • Efficacy should compare favorably to surgery – Primary endpoint of 5° reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake • Less severe contractures responded better than more severe contractures • MP joints r

Slide 18: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in

Slide 19: XIAFLEX Supply Chain
XIAFLEX Supply Chain • API produced in Horsham, PA – 2°- 8°C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophilization

Slide 20: Dupuytren's Contracture – an Unmet Medical Need
Dupuytren’s Contracture –an Unmet Medical Need Tubiana 2006. Hueston 1963 Skoog 1948 Mikkelsen 1976 • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to Million, in U.S. and EU, but occurs in all populations • Higher prevalence in patients of northern-European descent

Slide 21: Extensive Market Research Performed with Dupuytren's Surgeons
Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeo

Slide 22: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU
Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis

Slide 23: Commercial Target for Launch of XIAFLEX in Dupuytren's Contracture
Commercial Target for Launch of XIAFLEX in Dupuytren’s Contracture Stage I Stage II Stage III Not Seeking Treatment 12.5-26 Million pts Medical and Surgical Treatment 395,000 pts Watchful Waiting 635,000 pts

Slide 24: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~ 1M patients annually seeking treatment in U.S. and EU • Sustainable patient pool – New patients within an ageing population •

Slide 25: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/ d

Slide 26: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : - 293; La Pera et al : EUR Urology 2001: :525 - 530. Smith BH. Am

Slide 27: Current Surgical Options - Treatment of Last Resort
Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to att

Slide 28: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Reported Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a

Slide 29: Study 1030
Study 1030 Percent of patients a-i-er Month 3 Month 6 Month 9 Study 1035 Tae : | Week6 Month3 Month6 Months a Innovations for tite”

Slide 30: Peyronie's Phase IIb Study Enrollment Expected to Complete in 1Q09
Peyronie’s Phase IIb Study Enrollment Expected to Complete in 1Q09 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to main

Slide 31: Peyronie's Phase IIb Study Design
Peyronie’s Phase IIb Study Design 120 15 no Placebo D 45 no XIAFLEX C 15 yes Placebo B 45 yes XIAFLEX A Targeted Number of Patients Plaque Modeling Study Drug Arm • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.

Slide 32: Peyronie's Phase IIb Trial Utilizes a Novel Patient Reported Outcome
Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyro

Slide 33: Extensive Market Research Performed with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe

Slide 34: Annually, >210,000 Peyronie's Candidates Could Exist between U.S. and Europe
Annually, >210,000 Peyronie’s Candidates Could Exist between U.S. and Europe Source: 2006 Auxilium research and analysis

Slide 35: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in F

Slide 36: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver

Slide 37: Testim Remains the Fastest Growing Testosterone Replacement Therapy Gel
Testim ® Remains the Fastest Growing Testosterone Replacement Therapy Gel *Mulligan T. et al. Int J. Clin Pract 2006 • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal*

Slide 38: 447% +30%
447% +30%

Slide 39: Hid
: : ‘4 A ;= Hid | vumarlll a | —— = Qo a a Innovations tor

Slide 40: Net Revenues and TRx
Net Revenues ($ in at 02 03 @4 a1 a2 G3 G4 Ql 92 G3 G4 Gl @2 G3 @ ai G2 a3 2004 2005 2006 2007 2008 ~® TRX (in thousands) Hi Net Revenues ($ in millions) RXs (000's) ae Innovations tor tite

Slide 41: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan t

Slide 42: Q3 '08 Financial Results and 2008 Guidance
Revenues $32.6 $90.6 $120-125 R&D Expense $13.3 $39.9 $52-56 SG&A Expense $21.9 $65.1 $88-92 Net Loss ($10.1) ($34.1) ($44-48) Stock – Based Comp Expense $3.2 $8.1 $9-11 Cash & Cash Equivalents $46.4* Q3 ‘08 Financial Results and 2008 Guidance ($ Millions) 2008 Q3 ’08 9M’ Guidance Currently approxim

Slide 43: Strategic Priorities in 2009
Strategic Priorities in 2009 • File the XIAFLEX BLA for Dupuytren’s contracture, which we expect to achieve in early 2009; • Continue our pre-launch commercialization efforts for an anticipated U.S. launch of XIAFLEX in early 2010; • Complete enrollment in the Peyronie’s disease Phase IIb trial, whi

Slide 44: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories

Slide 45: January 2009
January 2009 (NASDAQ: AUXL)
Source: SEC EDGAR · 8-K filed Jan 12, 2009
More decks from Auxilium Pharmaceuticals Inc
Merger or Acquisition (December 2014)20 slides · Dec 3, 2014
Q3 2014 Earnings Presentation26 slides · Nov 5, 2014
Merger or Acquisition (November 2014)15 slides · Nov 5, 2014
Merger or Acquisition (October 2014)15 slides · Oct 15, 2014
Merger or Acquisition (October 2014)10 slides · Oct 10, 2014
Merger or Acquisition (October 2014)16 slides · Oct 9, 2014